TRML
Price:
$47.98
Market Cap:
$1.23B
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Industry
Biotechnology
IPO Date
2021-05-07
Stock Exchange
NASDAQ
Ticker
TRML
According to Tourmaline Bio, Inc.’s latest financial reports and current stock price. The company's current ROE is -30.50%. This represents a change of 296.00% compared to the average of -7.70% of the last 4 quarters.
The mean historical ROE of Tourmaline Bio, Inc. over the last ten years is -1.05%. The current -30.50% ROE has changed 2.80% with respect to the historical average. Over the past ten years (40 quarters), TRML's ROE was at its highest in in the June 2023 quarter at 37.92%. The ROE was at its lowest in in the June 2025 quarter at -8.91%.
Average
-1.05%
Median
-17.94%
Minimum
-45.86%
Maximum
99.84%
Discovering the peaks and valleys of Tourmaline Bio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 18.76%
Maximum Annual ROE = 99.84%
Minimum Annual Increase = -26817305.13%
Minimum Annual ROE = -45.86%
| Year | ROE | Change |
|---|---|---|
| 2024 | -24.40% | 18.76% |
| 2023 | -20.54% | -120.58% |
| 2022 | 99.84% | -26817305.13% |
| 2021 | -0.00% | -100.00% |
| 2020 | -15.34% | -66.55% |
The current ROE of Tourmaline Bio, Inc. (TRML) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
18.30%
5-year avg
7.91%
10-year avg
-1.05%
Tourmaline Bio, Inc.’s ROE is greater than Terns Pharmaceuticals, Inc. (-27.35%), greater than Precigen, Inc. (-5766.24%), greater than Immatics N.V. (-23.26%), greater than ORIC Pharmaceuticals, Inc. (-45.33%), greater than Enliven Therapeutics, Inc. (-29.15%), greater than Amylyx Pharmaceuticals, Inc. (-68.95%), greater than Relay Therapeutics, Inc. (-42.94%), greater than Dianthus Therapeutics, Inc. (-33.02%), greater than Wave Life Sciences Ltd. (-72.94%), greater than Syndax Pharmaceuticals, Inc. (-160.60%),
| Company | ROE | Market cap |
|---|---|---|
| -27.35% | $2.44B | |
| -5766.24% | $1.13B | |
| -23.26% | $1.44B | |
| -45.33% | $1.11B | |
| -29.15% | $1.27B | |
| -68.95% | $1.20B | |
| -42.94% | $1.39B | |
| -33.02% | $1.62B | |
| -72.94% | $1.25B | |
| -160.60% | $1.71B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tourmaline Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Tourmaline Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Tourmaline Bio, Inc.'s ROE?
How is the ROE calculated for Tourmaline Bio, Inc. (TRML)?
What is the highest ROE for Tourmaline Bio, Inc. (TRML)?
What is the 3-year average ROE for Tourmaline Bio, Inc. (TRML)?
What is the 5-year average ROE for Tourmaline Bio, Inc. (TRML)?
How does the current ROE for Tourmaline Bio, Inc. (TRML) compare to its historical average?